Wednesday, August 2, 2023

HomeStreet: Stressed West Coast Small-Regional Bank, Pursuing a Sale

›
HomeStreet (HMST) ($180MM market cap) is a small regional lender based in Seattle that flew a bit too close to the sun in 2021-2022 and is n...
32 comments:
Tuesday, August 1, 2023

Esperion Therapeutics: Litigation Special Situation, Potential Blockbuster Drug

›
This one is speculative, outside of the broken-biotech basket, but I still think it could be interesting in a small position size or LEAPs. ...
11 comments:
Thursday, July 20, 2023

Pieris Pharmaceuticals: Broken Biotech, Quirky Accounting, Possible Value Nuggets

›
The dumpster diving continues, this one is a bit messier and riskier. Pieris Pharmaceuticals (PIRS) is a clinical stage biotechnology compan...
32 comments:
Tuesday, July 18, 2023

MEI Pharma: Flawed Deal w/ INFI, Activist Target

›
MEI Pharma (MEIP) ($50MM market cap) is a fledgling clinical stage biotech that has a pending merger with Infinity Pharmaceuticals (INFI) (...
55 comments:
Wednesday, July 12, 2023

AVROBIO: Another Broken Biotech, Clinical Assets Potentially Worth Something

›
AVROBIO (AVRO) (~$76MM market cap) is the latest broken biotech that is trading below net cash to announce they are pursuing strategic alter...
23 comments:
Tuesday, July 11, 2023

Vertical Capital Income: NAV Slashed Ahead of Carlyle Closing

›
Another day with egg on my face.  Today, Vertical Capital Income (VCIP) announced that ahead of their pending closing with Carlyle, the fund...
8 comments:
Friday, June 30, 2023

Mid Year 2023 Portfolio Review

›
This will be more of a brief check-in rather than a full review.  Unfortunately, my recent spell of underperformance has continued into the ...
33 comments: